Voyager Therapeutics (VYGR) Cash & Current Investments (2014 - 2026)

Voyager Therapeutics (VYGR) has 13 years of Cash & Current Investments data on file, last reported at $141.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 40.06% year-over-year to $141.5 million; the trailing twelve-month figure through Mar 2026 stood at $141.5 million (down 40.06% YoY), and the FY2025 full-year result was $196.4 million, down 26.34% from the prior year.
• Cash & Current Investments declined to $141.5 million in Q1 2026, from $196.4 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $399.6 million in Q1 2024 to a low of $118.8 million in Q4 2022.
• A 5-year average of $233.9 million and a median of $230.9 million in 2023 frame the typical range for Cash & Current Investments.
• Across the five-year window, Cash & Current Investments jumped 94.26% in 2023 and sank 41.89% in 2025, its largest moves.
• Tracing VYGR's Cash & Current Investments over 5 years: stood at $118.8 million in 2022, then jumped by 94.26% to $230.9 million in 2023, then advanced by 15.51% to $266.7 million in 2024, then dropped by 26.34% to $196.4 million in 2025, then fell by 27.98% to $141.5 million in 2026.
• Business Quant data shows VYGR's Cash & Current Investments at $141.5 million in Q1 2026, $196.4 million in Q4 2025, and $208.9 million in Q3 2025.